You are here: Home / Patients and Families / Our Stories / Meeting of the Minds

Meeting of the Minds

Part 3 in a series on collaborations between researchers and clinicians
Dr. Irene Andrulis
Dr. Irene Andrulis
Dr Jay Wunder
Dr. Jay Wunder

“Researchers and clinicians internationally speak about the expertise of our sarcoma tumour group,” says Dr. Andrulis, who returned in mid-November from a research meeting in Paris at which scientists worldwide convened to present up-to-date research on sarcoma. “Here at Mount Sinai, we have specifically recruited research associates to collect and analyze patient tumours and data.” Through these multidisciplinary collaborations, Drs. Wunder and Andrulis also investigate biomedical and clinical questions in consultation with specialized pathologists, medical oncologists and radiation oncologists.

Dr. Andrulis notes that since Dr. Wunder first trained in her lab, several other surgical oncology fellows have studied molecular genetics with her team as well, so that they are skilled in both areas and understand the importance of translating their research findings to the clinic, for better patient outcomes.

The fellows and trainees—as well as colleagues at other hospitals in Toronto—all attend bi-monthly sarcoma rounds at which basic researchers and clinicians including Drs. Wunder, Ferguson, Gladdy and Swallow present their research and discuss clinical cases.

“I think it’s a really great model that other centres are hoping to replicate,” says Dr. Wunder. “It’s also an especially powerful paradigm for clinicians who want to conduct higher-end research, especially in the area of disease modeling. We can bring together our questions about the disease, and look at problems from several viewpoints.”

The partnership between Drs. Andrulis and Wunder also extends to their involvement in team grants such as those from the National Institutes of Health, as well as their involvement in large-scale sequencing projects. For example, a new project includes collaboration with researchers in British Columbia and internationally, and is designed to assess changes in the tumours of osteosarcoma patients and how these changes affect outcomes, as well as how more individualized therapies can be designed and targeted to unique tumour types. 


Meeting of the Minds: Part 1 »

Meeting of the Minds: Part 2 »